References
Doub JB. Bacteriophage therapy for clinical biofilm infections: parameters that influence treatment protocols and current treatment approaches. Antibiotics (Basel). 2020;9:799.
Dąbrowska K. Phage therapy: What factors shape phage pharmacokinetics and bioavailability? systematic and critical review. Med Res Rev. 2019;39:2000–25.
Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, Schooley R. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020;7:389.
Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, De Munter P, Debaveye Y, Nijs S, Vanderschot P, Wagemans J, Pirnay JP, Lavigne R, Metsemakers WJ. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11:891.
Chang RYK, Wallin M, Lin Y, Leung SSY, Wang H, Morales S, Chan HK. Phage therapy for respiratory infections. Adv Drug Deliv Rev. 2018;133:76–86.
Ferry T, Kolenda C, Batailler C, Gustave CA, Lustig S, Malatray M, et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front Med. 2020;7:570572.
Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J, Horne B, Brownstein MJ, Henry M, Malagon F, Biswas B. Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection. Antibiotics (Basel). 2020;9:241.
Hansen MF, Svenningsen SL, Røder HL, Middelboe M, Burmølle M. Big impact of the tiny: bacteriophage-bacteria interactions in biofilms. Trends Microbiol. 2019;27:739–52.
Roy ME, Peppers MP, Whiteside LA, Lazear RM. Vancomycin concentration in synovial fluid: direct injection into the knee vs. intravenous infusion. J Arthroplasty. 2014;29:564–8.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None to declare.
Ethical approval
All patients gave informed consent to be administered bacteriophage therapy for their recalcitrant infections and to publish their cases and/or data. All patients included had individual IND’s granted by the FDA through the expanded access pathway. These were individually reviewed and approved by the University of Maryland IRB.
Rights and permissions
About this article
Cite this article
Doub, J.B., Wilson, E. Observed transaminitis with a unique bacteriophage therapy protocol to treat recalcitrant Staphylococcal biofilm infections. Infection 50, 281–283 (2022). https://doi.org/10.1007/s15010-021-01675-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-021-01675-w